{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:53:48Z","timestamp":1790610828988,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shaanxi Science and Technology Association youth talent lifting program","award":["20230329"],"award-info":[{"award-number":["20230329"]}]},{"name":"Shaanxi Provincial People\u2019s Hospital science and technology development incubation fund project","award":["2023YJY-51"],"award-info":[{"award-number":["2023YJY-51"]}]},{"name":"Shaanxi Provincial Science and Technology Department Key Research and Development Program","award":["2025SF-YBXM-394"],"award-info":[{"award-number":["2025SF-YBXM-394"]}]},{"name":"Shaanxi Provincial Administration of Traditional Chinese Medicine Research Project","award":["2023-JC-005"],"award-info":[{"award-number":["2023-JC-005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-33039-x","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:45:05Z","timestamp":1765997105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["MTHFR and ABCB1 polymorphisms associated with toxicity in hematological malignancies patients receiving high dose methotrexate"],"prefix":"10.1038","volume":"16","author":[{"given":"Yaling","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"12","key":"33039_CR1","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1634\/theoncologist.2015-0164","volume":"21","author":"SC Howard","year":"2016","unstructured":"Howard, S. C., McCormick, J., Pui, C. H., Buddington, R. K. & Harvey, R. D. Preventing and managing toxicities of High-Dose methotrexate. Oncologist 21 (12), 1471\u20131482 (2016).","journal-title":"Oncologist"},{"issue":"6","key":"33039_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1586\/ecp.11.57","volume":"4","author":"D Lev\u00eaque","year":"2011","unstructured":"Lev\u00eaque, D., Santucci, R., Gourieux, B. & Herbrecht, R. Pharmacokinetic drug-drug interactions with methotrexate in oncology. Expert Rev. Clin. Pharmacol. 4 (6), 743\u2013750 (2011).","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"10","key":"33039_CR3","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1080\/10428194.2022.2074987","volume":"63","author":"J Wight","year":"2022","unstructured":"Wight, J. et al. Toxicity associated with high-dose intravenous methotrexate for hematological malignancies. Leuk. Lymphoma. 63 (10), 2375\u20132382 (2022).","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"33039_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00280-016-3043-5","volume":"78","author":"JM Campbell","year":"2016","unstructured":"Campbell, J. M. et al. Methotrexate-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Cancer Chemother. Pharmacol. 78 (1), 27\u201339 (2016).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"33039_CR5","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","volume":"23","author":"LB Ramsey","year":"2018","unstructured":"Ramsey, L. B. et al. Consensus guideline for use of glucarpidase in patients with High-Dose methotrexate induced acute kidney injury and delayed methotrexate clearance. Oncologist 23 (1), 52\u201361 (2018).","journal-title":"Oncologist"},{"issue":"7","key":"33039_CR6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ajhg.2021.05.009","volume":"108","author":"J Weile","year":"2021","unstructured":"Weile, J. et al. Shifting landscapes of human MTHFR missense-variant effects. Am. J. Hum. Genet. 108 (7), 1283\u20131300 (2021).","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"33039_CR7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1042\/CS20180932","volume":"133","author":"YC Wang","year":"2019","unstructured":"Wang, Y. C. et al. MTHFR C677T polymorphism increases MTX sensitivity via the Inhibition of S-adenosylmethionine and de Novo purine synthesis. Clin. Sci. (Lond). 133 (2), 253\u2013267 (2019).","journal-title":"Clin. Sci. (Lond)"},{"issue":"5","key":"33039_CR8","first-page":"546","volume":"24","author":"R Takatori","year":"2006","unstructured":"Takatori, R. et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin. Exp. Rheumatol. 24 (5), 546\u2013554 (2006).","journal-title":"Clin. Exp. Rheumatol."},{"key":"33039_CR9","doi-asserted-by":"publisher","first-page":"759805","DOI":"10.3389\/fonc.2021.759805","volume":"11","author":"J Han","year":"2021","unstructured":"Han, J. et al. Effect of polymorphisms of ABCB1 and MTHFR on Methotrexate-Related toxicities in adults with hematological malignancies. Front. Oncol. 11, 759805 (2021).","journal-title":"Front. Oncol."},{"key":"33039_CR10","doi-asserted-by":"publisher","first-page":"781386","DOI":"10.3389\/fonc.2021.781386","volume":"11","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. MTHFR polymorphism is associated with severe Methotrexate-Induced toxicity in osteosarcoma treatment. Front. Oncol. 11, 781386 (2021).","journal-title":"Front. Oncol."},{"key":"33039_CR11","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2147\/IJGM.S453394","volume":"17","author":"Q Guo","year":"2024","unstructured":"Guo, Q., Sun, J. L., Li, R. & Li, X. Involvement of the ABCB1 C3435T variant but not the MTHFR C677T or MTHFR A1298C variant in High-Dose Methotrexate-Induced toxicity in pediatric acute lymphoblastic leukemia patients in China. Int. J. Gen. Med. 17, 1221\u20131231 (2024).","journal-title":"Int. J. Gen. Med."},{"key":"33039_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.clml.2020.08.020","volume":"21","author":"X Chang","year":"2021","unstructured":"Chang, X. et al. Influence of MTHFR C677T polymorphism on High-Dose Methotrexate-Related toxicity in patients with primary central nervous system diffuse large B-Cell lymphoma. Clin. Lymphoma Myeloma Leuk. 21, 91\u201396 (2021).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"e1","key":"33039_CR13","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1136\/ejhpharm-2020-002477","volume":"29","author":"YX Yu","year":"2022","unstructured":"Yu, Y. X. et al. Predictive performance of reported Vancomycin population Pharmacokinetic model in patients with different renal function status, especially those with augmented renal clearance. Eur. J. Hosp. Pharm. 29 (e1), e6\u2013e14 (2022).","journal-title":"Eur. J. Hosp. Pharm."},{"key":"33039_CR14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12911-023-02248-7","volume":"23","author":"C Jian","year":"2023","unstructured":"Jian, C. et al. Predicting delayed methotrexate elimination in pediatric acute lymphoblastic leukemia patients: an innovative web-based machine learning tool developed through a multicenter, retrospective analysis. BMC Med. Inf. Decis. Mak. 23, 148 (2023).","journal-title":"BMC Med. Inf. Decis. Mak."},{"key":"33039_CR15","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1111\/jcpt.13791","volume":"47","author":"K Sun","year":"2022","unstructured":"Sun, K. et al. Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma. J. Clin. Pharm. Ther. 47, 2196\u20132204 (2022).","journal-title":"J. Clin. Pharm. Ther."},{"issue":"2","key":"33039_CR16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00431-023-05267-8","volume":"183","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y. et al. Effects of gene polymorphisms on delayed MTX clearance, toxicity, and metabolomic changes after HD-MTX treatment in children with acute lymphoblastic leukemia. Eur. J. Pediatr. 183 (2), 581\u2013590 (2024).","journal-title":"Eur. J. Pediatr."},{"key":"33039_CR17","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/00498254.2024.2320778","volume":"54","author":"K Shendy","year":"2024","unstructured":"Shendy, K. et al. The effects of genetic polymorphism on toxicity and pharmacokinetics of methotrexate in Egyptian adult patients with leukaemia or lymphoma. Xenobiotica 54, 95\u2013105 (2024).","journal-title":"Xenobiotica"},{"key":"33039_CR18","doi-asserted-by":"publisher","first-page":"155810","DOI":"10.1016\/j.phymed.2024.155810","volume":"132","author":"Q Nian","year":"2024","unstructured":"Nian, Q., Liu, R. & Zeng, J. Unraveling the pathogenesis of myelosuppression and therapeutic potential of natural products. Phytomedicine 132, 155810 (2024).","journal-title":"Phytomedicine"},{"issue":"1","key":"33039_CR19","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12957-023-03287-0","volume":"22","author":"B Liu","year":"2024","unstructured":"Liu, B. et al. Correlation between gene polymorphism and adverse reactions of high-dose methotrexate in osteosarcoma patients: a systematic review and meta-analysis. World J. Surg. Oncol. 22 (1), 19 (2024).","journal-title":"World J. Surg. Oncol."},{"issue":"6","key":"33039_CR20","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1080\/1120009X.2021.2009723","volume":"34","author":"A Ebid","year":"2022","unstructured":"Ebid, A. et al. High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C\u2009>\u2009T rs1045642 and MTHFR 677C\u2009>\u2009T rs1801133 polymorphisms on toxicities and delayed elimination. J. Chemother. 34 (6), 381\u2013390 (2022).","journal-title":"J. Chemother."},{"key":"33039_CR21","doi-asserted-by":"publisher","first-page":"15119","DOI":"10.1038\/s41598-024-65199-7","volume":"14","author":"QM Mutlak","year":"2024","unstructured":"Mutlak, Q. M. & Kasim, A. A. Impact of MTHFR gene polymorphism on the outcome of methotrexate treatment in a sample of Iraqi rheumatoid arthritis patients. Sci. Rep. 14, 15119 (2024).","journal-title":"Sci. Rep."},{"key":"33039_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1080\/1120009X.2020.1764280","volume":"32","author":"H Chae","year":"2020","unstructured":"Chae, H. et al. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia. J. Chemother. 32, 251\u2013259 (2020).","journal-title":"J. Chemother."},{"key":"33039_CR23","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1515\/biol-2021-0121","volume":"16","author":"Y Shen","year":"2021","unstructured":"Shen, Y., Wang, Z., Zhou, F. & Jin, R. The influence of MTHFR genetic polymorphisms on methotrexate therapy in pediatric acute lymphoblastic leukemia. Open. Life Sci. 16, 1203\u20131212 (2021).","journal-title":"Open. Life Sci."},{"key":"33039_CR24","doi-asserted-by":"publisher","first-page":"1130548","DOI":"10.3389\/fphar.2023.1130548","volume":"14","author":"A El Masri","year":"2023","unstructured":"El Masri, A. et al. Case report: hepatotoxicity and nephrotoxicity induced by methotrexate in a paediatric patient, what is the role of precision medicine in 2023. Front. Pharmacol. 14, 1130548 (2023).","journal-title":"Front. Pharmacol."},{"key":"33039_CR25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.21037\/tp-22-671","volume":"12","author":"Y Tan","year":"2023","unstructured":"Tan, Y. et al. Relationship between methylenetetrahydrofolate reductase gene polymorphisms and methotrexate drug metabolism and toxicity. Transl Pediatr. 12, 31\u201345 (2023).","journal-title":"Transl Pediatr."},{"issue":"11","key":"33039_CR26","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2217\/pgs.14.97","volume":"15","author":"S Suthandiram","year":"2014","unstructured":"Suthandiram, S. et al. Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics 15 (11), 1479\u20131494 (2014).","journal-title":"Pharmacogenomics"},{"key":"33039_CR27","doi-asserted-by":"publisher","first-page":"103312","DOI":"10.1016\/j.critrevonc.2021.103312","volume":"161","author":"H Maagdenberg","year":"2021","unstructured":"Maagdenberg, H. et al. Genetic variants associated with methotrexate-induced mucositis in cancer treatment: A systematic review and meta-analysis. Crit. Rev. Oncol. Hematol. 161, 103312 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"6","key":"33039_CR28","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1111\/jcpt.13505","volume":"46","author":"Y Gong","year":"2021","unstructured":"Gong, Y. et al. Association of MTHFR and ABCB1 polymorphisms with MTX-induced mucositis in Chinese paediatric patients with acute lymphoblastic leukaemia, lymphoma or osteosarcoma-A retrospective cohort study. J. Clin. Pharm. Ther. 46 (6), 1557\u20131563 (2021).","journal-title":"J. Clin. Pharm. Ther."},{"key":"33039_CR29","first-page":"919","volume":"15","author":"J Wang","year":"2022","unstructured":"Wang, J., Zhao, Y. T., Sun, M. J., Chen, F. & Guo, H. L. The role of single nucleotide polymorphisms in transporter proteins and the folate metabolism pathway in delayed methotrexate excretion: A case report and literature review. Pharmgenomics Pers. Med. 15, 919\u2013926 (2022).","journal-title":"Pharmgenomics Pers. Med."},{"key":"33039_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3389\/fped.2020.00307","volume":"8","author":"M Cwiklinska","year":"2020","unstructured":"Cwiklinska, M. et al. Polymorphisms of SLC19A1 80 G\u2009>\u2009A, MTHFR 677 C\u2009>\u2009T, and tandem TS repeats influence Pharmacokinetics, acute liver Toxicity, and vomiting in children with acute lymphoblastic leukemia treated with high doses of methotrexate. Front. Pediatr. 8, 307 (2020).","journal-title":"Front. Pediatr."},{"issue":"1","key":"33039_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00280-022-04498-0","volume":"91","author":"M Li","year":"2023","unstructured":"Li, M., Kong, X. Y. & Wang, S. M. Effects of splicing-regulatory polymorphisms in ABCC2, ABCG2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia. Cancer Chemother. Pharmacol. 91 (1), 77\u201387 (2023).","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"5","key":"33039_CR32","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s12185-020-03071-w","volume":"113","author":"T Nakano","year":"2021","unstructured":"Nakano, T. et al. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma. Int. J. Hematol. 113 (5), 744\u2013750 (2021).","journal-title":"Int. J. Hematol."},{"issue":"2","key":"33039_CR33","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hon.2479","volume":"36","author":"F Ranchon","year":"2018","unstructured":"Ranchon, F. et al. Delayed methotrexate elimination: Incidence, interaction with antacid drugs, and clinical consequences. Hematol. Oncol. 36 (2), 399\u2013406 (2018).","journal-title":"Hematol. Oncol."},{"issue":"6","key":"33039_CR34","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.21873\/invivo.12185","volume":"34","author":"KO Misaka","year":"2020","unstructured":"Misaka, K. O. et al. Risk factors for delayed elimination of methotrexate in Children, adolescents and young adults with osteosarcoma. Vivo 34 (6), 3459\u20133465 (2020).","journal-title":"Vivo"},{"issue":"1","key":"33039_CR35","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2125.2008.03303.x","volume":"67","author":"K Suzuki","year":"2009","unstructured":"Suzuki, K. et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br. J. Clin. Pharmacol. 67 (1), 44\u201349 (2009).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"33039_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11096-019-00958-5","volume":"42","author":"X Wang","year":"2020","unstructured":"Wang, X. et al. Effect of proton pump inhibitors on high-dose methotrexate elimination: a systematic review and meta-analysis. Int. J. Clin. Pharm. 42 (1), 23\u201330 (2020).","journal-title":"Int. J. Clin. Pharm."},{"issue":"5","key":"33039_CR37","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1007\/s43440-020-00130-1","volume":"72","author":"H Ueda","year":"2020","unstructured":"Ueda, H. et al. Evaluation of possible Pharmacokinetic interaction between methotrexate and proton pump inhibitors in rats. Pharmacol. Rep. 72 (5), 1426\u20131432 (2020).","journal-title":"Pharmacol. Rep."},{"key":"33039_CR38","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1177\/10781552211017193","volume":"28","author":"R Frikha","year":"2022","unstructured":"Frikha, R., Elloumi, M., Rebai, T. & Kamoun, H. MTHFR 677T-1298\u00a0C haplotype in acute lymphoblastic leukemia: impact on methotrexate therapy. J. Oncol. Pharm. Pract. 28, 1031\u20131034 (2022).","journal-title":"J. Oncol. Pharm. Pract."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33039-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33039-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33039-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T02:04:50Z","timestamp":1769220290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-33039-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["33039"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-33039-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3114"}}